2011 Update of Scientific Statement for the Primary Prevention of Stroke: Dyslipidemia and Inflammation.
- Author:
Sang Won HAN
1
;
Hahn Young KIM
;
Jong Moo PARK
;
Jaseong KOO
;
Yong Jin CHO
;
Kyusik KANG
;
Kyung Ho YU
;
Joung Ho RHA
;
Ji Hoe HEO
;
Sun Uck KWON
;
Chang Wan OH
;
Hee Joon BAE
;
Byung Chul LEE
;
Byung Woo YOON
;
Chin Sang CHUNG
;
Keun Sik HONG
Author Information
1. Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
- Publication Type:Review ; Clinical Trial
- Keywords:
Dyslipidemia;
Inflammation;
Primary prevention;
Scientific statement;
Stroke
- MeSH:
Cholesterol;
Dyslipidemias;
Eye;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Inflammation;
Lipoproteins;
Meta-Analysis as Topic;
Practice Guidelines as Topic;
Primary Prevention;
Stroke;
Writing
- From:Journal of the Korean Neurological Association
2012;30(3):159-169
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This scientific statement is intended to provide a systematic review of new evidences in dyslipidemia and inflammation for primary stroke prevention. METHODS: Using a structured literature search, we identified major observational studies, clinical trials, meta-analyses, and updated major guidelines published between July 2007 and November 2010. In addition to the brief summary of earlier evidences employed in the first edition of Korean clinical practice guideline for primary prevention of stroke, we summarized the newly identified evidences. RESULTS: For dyslipidemia, observational studies further support a strong association between ischemic stroke and high total and low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol. Two clinical trials and 6 meta-analyses confirm statin efficacy for primary prevention of stroke in high risk patients. Efficacy of other lipid-lowering agents is not established. For inflammation, inflammatory markers might help to identify patients having high risk for stroke or cardiovascular event and to decide whether statin therapy is indicated, but its usefulness for broad population needs to be confirmed. CONCLUSIONS: Writing committee will continue to keep an eye on upcoming evidences to timely update the guideline for primary stroke prevention in dyslipidemia and inflammation.
